Breakdown | |||||
TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
6.97M | 9.06M | 6.09M | 5.76M | 5.26M | 7.04M | Gross Profit |
6.97M | 9.06M | 6.09M | 5.76M | 4.96M | 5.61M | EBIT |
-15.01M | -11.63M | -13.30M | -12.36M | -18.07M | -20.90M | EBITDA |
-14.88M | -11.83M | -13.32M | -12.31M | -17.99M | -20.85M | Net Income Common Stockholders |
-18.83M | -16.22M | -17.49M | -14.90M | -21.00M | -20.21M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
39.16M | 12.60M | 22.77M | 34.59M | 31.25M | 39.16M | Total Assets |
60.29M | 25.87M | 37.20M | 50.49M | 51.20M | 60.29M | Total Debt |
16.89M | 48.41M | 45.66M | 43.08M | 26.34M | 16.89M | Net Debt |
-5.17M | 42.08M | 32.24M | 18.06M | 13.13M | -5.17M | Total Liabilities |
23.49M | 55.77M | 51.23M | 47.38M | 33.95M | 23.49M | Stockholders Equity |
36.80M | -29.91M | -14.03M | 3.11M | 17.25M | 36.80M |
Cash Flow | Free Cash Flow | ||||
-13.38M | -10.15M | -11.11M | -11.46M | -15.62M | -22.03M | Operating Cash Flow |
-13.37M | -10.14M | -11.09M | -11.45M | -15.59M | -21.98M | Investing Cash Flow |
5.27M | 3.25M | -317.00K | 8.42M | -616.00K | -932.00K | Financing Cash Flow |
8.28M | -192.00K | -186.00K | 14.83M | 7.37M | 17.34M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
72 Outperform | CHF557.64M | 7.24 | ― | 32.30% | 631.04% | ||
68 Neutral | CHF145.52M | 10.37 | ― | 450.19% | ― | ||
53 Neutral | $5.25B | 3.24 | -45.38% | 2.81% | 16.79% | -0.06% | |
51 Neutral | CHF382.17M | ― | ― | 11.61% | -356.20% | ||
50 Neutral | CHF121.12M | ― | -40.40% | ― | -66.82% | 4.14% | |
44 Neutral | $127.16M | 2.58 | -93.91% | ― | -62.17% | -166.33% |
Newron Pharmaceuticals has received approval for its pivotal Phase III development program ENIGMA-TRS, which will evaluate Evenamide as an add-on therapy for treatment-resistant schizophrenia (TRS). This program, consisting of two studies, aims to meet regulatory requirements for marketing authorization in major markets like the USA and Europe. The approval marks a significant step for Newron, potentially enhancing its market position by addressing the unmet medical need for effective TRS treatments. The studies will assess the efficacy, tolerability, and safety of Evenamide, with patient recruitment starting immediately and results expected in late 2026.
Newron Pharmaceuticals announced the approval of its pivotal Phase-III development program ENIGMA-TRS, which includes two studies to evaluate Evenamide as an add-on therapy for treatment-resistant schizophrenia (TRS). The studies, ENIGMA-TRS 1 and ENIGMA-TRS 2, aim to address the unmet medical need for effective treatments in TRS patients by targeting the glutamatergic system, offering a new therapeutic option for those who do not respond adequately to current antipsychotics.
Newron Pharmaceuticals announced the election of Dr. Chris Martin as the new Chairman of the Board during their 2025 General Meeting. The meeting also extended a capital increase until 2028, although some agenda items were not voted on due to a lack of quorum. This leadership change and financial strategy adjustment may influence Newron’s future operations and strategic direction, especially in the context of their ongoing drug development efforts.
Newron Pharmaceuticals reported significant progress in 2024, highlighted by promising data from studies on Evenamide, a potential treatment for schizophrenia. The company secured strategic licensing agreements with EA Pharma and Myung In Pharm, enhancing its market presence in Asia and supporting its upcoming Phase III study. With a net profit of EUR 15.8 million, Newron is poised for further growth in 2025, driven by its robust financial position and strategic partnerships.
Newron Pharmaceuticals reported a net profit of EUR 15.8 million for 2024, a significant turnaround from the previous year’s loss, driven by licensing revenues from agreements with EA Pharma/Eisai Group and Myung In Pharm. The company has strengthened its financial position and expanded its market reach through strategic partnerships and capital measures, positioning itself for further growth in 2025 with plans to advance Evenamide’s development and potentially register its shares in the USA.